Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
antibody levels
immune reconstitution
immunization
infections
lymphodepletion
titers
vaccination
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
31 Oct 2021
31 Oct 2021
Historique:
received:
05
10
2021
revised:
26
10
2021
accepted:
29
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study aimed to assess the influence of CLAD treatment on specific antibody titers to common pathogens. We included 18 MS patients treated with CLAD. Serum IgG antibody levels to measles, mumps, rubella, hepatitis B and varicella zoster virus (VZV), as well as diphtheria and tetanus toxins, were measured prior to the initiation of treatment and at 12 and 24 months after first CLAD administration. Moreover, specimens were longitudinally analyzed regarding absolute blood concentrations of IgG and main lymphocyte subsets. No reduction in antibody levels against measles, mumps, rubella, VZV, hepatitis B, diphtheria toxin and tetanus toxin associated with CLAD treatment was observed. Loss of seroprotection occurred in <1%. We found no significant impact of CLAD on absolute serum IgG levels. Absolute lymphocyte counts were significantly reduced at the end of each treatment year (
Identifiants
pubmed: 34829815
pii: biomedicines9111584
doi: 10.3390/biomedicines9111584
pmc: PMC8615381
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Immunol Res. 2020 Dec;68(6):325-339
pubmed: 33161557
Neurol Neuroimmunol Neuroinflamm. 2019 Dec 11;7(2):
pubmed: 31826986
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Autoimmun Rev. 2020 Oct;19(10):102647
pubmed: 32801039
Mult Scler. 2011 May;17(5):578-93
pubmed: 21228029
Mult Scler. 2018 Oct;24(12):1594-1604
pubmed: 28870107
Cell. 2019 Apr 18;177(3):524-540
pubmed: 31002794
J Neuroophthalmol. 2018 Jun;38(2):251-258
pubmed: 29561328
Ther Adv Neurol Disord. 2018 Jan 23;11:1756285617753365
pubmed: 29399054
Trends Pharmacol Sci. 2018 Oct;39(10):892-904
pubmed: 30143244
Mult Scler Relat Disord. 2019 Jan;27:117-120
pubmed: 30368223
Science. 2020 Sep 25;369(6511):
pubmed: 32973003
EBioMedicine. 2017 Feb;16:41-50
pubmed: 28161400
Clin Exp Immunol. 2018 Dec;194(3):295-314
pubmed: 30144037
Clin Pharmacokinet. 2019 Mar;58(3):283-297
pubmed: 29987837
Expert Rev Vaccines. 2010 Jun;9(6):567-78
pubmed: 20518713
Mult Scler Relat Disord. 2021 Sep;54:103150
pubmed: 34298478
Lancet Neurol. 2014 Mar;13(3):257-67
pubmed: 24502830
Mult Scler Relat Disord. 2019 Apr;29:157-167
pubmed: 30885374
J Neurol. 2018 May;265(5):1199-1209
pubmed: 29550884
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
N Engl J Med. 2010 Feb 4;362(5):416-26
pubmed: 20089960
Neurotherapeutics. 2017 Oct;14(4):874-887
pubmed: 29168160
Mult Scler. 2019 Oct;25(12):1605-1617
pubmed: 30289355
Ann Clin Transl Neurol. 2020 Nov;7(11):2199-2212
pubmed: 33002321
Ther Adv Neurol Disord. 2019 Jun 18;12:1756286419854986
pubmed: 31244898
Neurology. 2019 Sep 24;93(13):584-594
pubmed: 31462584